La vendita allo scoperto per Inari Medical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Inari Medical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Inari Medical (NASDAQ:NARI) Azioni, Report sulle vendite allo scoperto

Inari Medical

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Inari Medical Inc

<a href="https://www.atlantafed.org/news/press-room/media-advisories/2024/10/18/bostic-lecture-millsaps-college-mississippi" title="https://www.atlantafed.org/news/press-room/media-advisories/2024/10/18/bostic-lecture-millsaps-college-mississippi">https://www.atlantafed.org/news/press-room/media-advisories/2024/10/18/bostic-lecture-millsaps-college-mississippi</a>

News

Federal Reserve

Fed's Bostic Says May See A Lull In Investment Activity, Household Spending Amid Election Uncertainty

BlackRock&#8217;s iShares Bitcoin Trust&nbsp;(NASDAQ:&nbsp;IBIT) ETF has attracted over $1 billion in inflows this week alone, which has helped propel the apex crypto to a <a href="https://www.tradingview.com/news/benzinga:01854bfbd094b:0-bitcoin-takes-aim-at-all-time-highs-what-does-it-mean-for-altcoins/">10% seven-day gain</a>.
What Happened: According to <a href="https://sosovalue.xyz/assets/etf/us-btc-spot">data</a> from SoSo Value, <a href="https://www.benzinga.com/topic/bitcoin-etf">spot bitcoin ETFs</a> in the U.S. garnered $470 million on Thursday alone. BlackRock&#8217;s IBIT was the frontrunner, pulling in $309 million, contributing to a total of $1.07 billion for the week.
Overall, spot bitcoin ETFs have experienced significant inflows, with 12 funds amassing over $1.85 billion this week. Ark and 21Shares&#8217; (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>) saw over $100 million in inflows. Grayscale&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#OTC">GBTC</a>) recorded $45.70 million, while Fidelity&#8217;s (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>) had $11.69 million. 
According to crypto analyst Rachael Lucas, <a href="https://www.theblock.co/post/321888/blackrock-spot-bitcoin-etf-draws-in-1-billion-so-far-this-week?utm_source=rss&amp;utm_medium=rss">per</a> The Block, this trend is due to favorable macroeconomic conditions. When central banks reduce interest rates, investors explore alternative assets.
Thursday&#8217;s trading volume for bitcoin ETFs was approximately $1.47 billion, slightly lower than the previous day. Since January, cumulative net inflows have reached $20.66 billion, a milestone <a href="https://x.com/EricBalchunas/status/1846885254356770924">described</a> by Bloomberg&#8217;s Eric Balchunas as &#8220;the most important metric in ETF world.&#8221;
Spot Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ETFs also reported positive flows, with $48.41 million on Thursday. Fidelity&#8217;s (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FETH#BATS">FETH</a>) led with $31.12 million, followed by BlackRock&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>) with $23.56 million. Despite these gains, Grayscale&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ETHE#OTC">ETHE</a>) experienced $15.74 million in outflows.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41391989/exclusive-robinhoods-bitstamp-deal-will-drive-growth-exec-says-what-was-good-for-stocks-we">EXCLUSIVE: Robinhood&#8217;s Bitstamp Deal Will Drive Growth, Exec Says: &#8216;What Was Good For Stocks &#8230; We Brought Into Crypto&#8217;</a>
Why It Matters: The surge in inflows Bitcoin ETFs comes as the cryptocurrency industry continues to grow according to important metrics. 
According to a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41386011/bitcoin-etfs-ethereum-staking-stablecoins-power-crypto-growth-in-2024-coinbase-report">recent report</a> by Coinbase and Glassnode, the crypto market is maturing, with successful spot ETFs and increased trading volumes cited as key growth drivers. Venture capital firm a16z found in a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41383239/crypto-hits-unprecedented-growth-7-major-findings-from-2024-report">separate report</a> that monthly active addresses are at all-time highs, up thrice from levels at the end of 2023.
The Securities and Exchange Commission had approved Bitcoin ETFs in January this year, following a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41386377/arrest-made-in-sec-x-account-hack-prior-to-bitcoin-etf-approval-fbi-says-phone-used-to-man">controversial incident</a> involving a hack of the SEC&#8217;s account.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41389551/musk-cuban-or-saylor-whos-the-biggest-crypto-influencer-benzinga-readers-have-an-overwhelm">Musk, Cuban, Or Saylor: Who&#8217;s The Biggest Crypto Influencer? Benzinga Readers Have An Overwhelming Favorite</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

ETHA

ETHE

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

Fidelity Ethereum Fund Fidelity Ethereum Fund

FETH

GBTC

IBIT

BlackRock's Bitcoin ETF Gobbles Up $1B This Week, Fidelity Leads Among Ethereum ETFs With $31M

Piper Sandler analyst Scott Siefers maintains Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Underweight and raises the price target from $14 to $15.

Price Target

Analyst Ratings

HBAN

Piper Sandler Maintains Underweight on Huntington Bancshares, Raises Price Target to $15

Canaccord Genuity analyst George Gianarikas maintains ASP Isotopes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) with a Buy and maintains $4.5 price target.

ASPI

Canaccord Genuity Maintains Buy on ASP Isotopes, Maintains $4.5 Price Target

In the current market session, PNC Finl Servs Gr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) stock price is at $188.60, after a 0.11% decrease. However, over the past month, the company's stock spiked by 1.20%, and in the past year, by 71.91%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1729261810_0.png" alt="Past Year Chart" />

<h3>Evaluating PNC Finl Servs Gr P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 13.44 in the Banks industry, PNC Finl Servs Gr Inc. has a higher P/E ratio of 15.96. Shareholders might be inclined to think that PNC Finl Servs Gr Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729261810_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for PNC Finl Servs Gr

Canaccord Genuity analyst Kingsley Crane maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Hold and lowers the price target from $90 to $82.

OKTA

Canaccord Genuity Maintains Hold on Okta, Lowers Price Target to $82

Piper Sandler analyst Stephen Scouten maintains Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) with a Overweight and raises the price target from $30 to $31.

HOMB

Piper Sandler Maintains Overweight on Home BancShares, Raises Price Target to $31

Bernstein analyst Laurent Yoon maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Market Perform and raises the price target from $625 to $780.

NFLX

Bernstein Maintains Market Perform on Netflix, Raises Price Target to $780

Canaccord Genuity analyst Maria Ripps maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Hold and raises the price target from $750 to $760.

Canaccord Genuity Maintains Hold on Netflix, Raises Price Target to $760

Piper Sandler analyst Nathan Race maintains Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) with a Overweight and raises the price target from $22.5 to $23.

OSBC

Piper Sandler Maintains Overweight on Old Second Bancorp, Raises Price Target to $23

U.S. stocks traded mixed this morning, with the Dow Jones falling over 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.35% to 43,086.52 while the NASDAQ rose 0.73% to 18,507.31. The S&amp;P 500 also rose, gaining, 0.26% to 5,856.65.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Communication services shares jumped by 1.4% on Friday.
In trading on Friday, energy shares fell by 0.6%.
Top Headline
Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected third-quarter financial results, posting revenue of $9.825 billion, up 15% year-over-year, versus market estimates of $9.769 billion.
The company ended the third quarter with 282.72 million global paid subscribers, up 14.4% year-over-year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Catheter Precision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NASDAQ">VTAK</a>) shares shot up 249% to $1.54.</li>
<li>Shares of Bright Minds Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) got a boost, surging 133% to $50.66. The company announced a $35 million non-brokered private placement.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares were also up, gaining 96% to $15.55 after the company announced it filed a form RW and will not pursue a public offering at this time.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares dropped 38% to $0.4301.</li>
<li>Shares of Orgenesis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) were down 34% to $2.1100.</li>
<li>NuZee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) was down, falling 31% to $1.5950.</li>
</ul>
Commodities In commodity news, oil traded down 1.5% to $69.59 while gold traded up 0.8% at $2,730.00.
Silver traded up 2.9% to $32.690 on Friday, while copper rose 1.3% to $4.3815.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.1%, Germany's DAX rose 0.2% and France's CAC 40 climbed 0.2%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 fell 0.8%.
Construction output in the Eurozone fell by 2.5% year-over-year in August compared to a revised 2.3% decline in the previous month. The current account surplus in the Eurozone increased to €35.2 billion in August from €26.8 billion in the year-ago period.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index climbing 3.61%, China's Shanghai Composite Index gaining 2.91% and India's BSE Sensex gaining 0.27%.
Economics
<ul>
<li>U.S. housing starts fell by 0.5% from the previous month to an annualized rate of 1.354 million units in September.</li>
<li>Building permits declined by 2.9% to an annual rate of 1.428 million in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41402086/wall-streets-most-accurate-analysts-give-their-take-on-3-financials-stocks-delivering-hi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Trading Ideas

DRUG

NKGN

NUZE

ORGS

SOBR

VTAK

Dow Falls Over 100 Points; Netflix Posts Upbeat Results

Piper Sandler analyst Stephen Scouten maintains Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) with a Overweight and raises the price target from $58 to $63.

Piper Sandler Maintains Overweight on Bank OZK, Raises Price Target to $63

Canaccord Genuity analyst Brian McNamara maintains Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) with a Buy and maintains $13 price target.

HLMN

Canaccord Genuity Maintains Buy on Hillman Solns, Maintains $13 Price Target

Argus Research downgrades Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) from Buy to Hold.

Downgrades

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Argus Research Downgrades Elevance Health to Hold

Canaccord Genuity analyst Maria Ripps maintains Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Hold and raises the price target from $11 to $13.

Canaccord Genuity Maintains Hold on Viant Technology, Raises Price Target to $13

Autoliv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41398774/autoliv-financial-report-july-september-2024" rel="noreferrer noopener">trading higher on Friday.</a>
The company reported third-quarter adjusted earnings per share of $1.84, missing the analyst consensus of $1.95. Quarterly revenues of $2.56 billion topped the street view of $2.53 billion.
In the third quarter, sales fell by 0.8% organically. The firm performed well in Europe and Asia (excluding China) due to numerous product launches and favorable pricing.
Sales to domestic Chinese OEMs increased by 18%, outpacing their LVP growth of 8.5%. 
However, the firm struggled in China because of a negative mix, with sales of lower-safety models rising while higher-end models declined.
The company&#8217;s adjusted operating margin decreased to 9.3% from 9.4%.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/10/41399541/apple-iphone-16-sees-20-sales-surge-in-china-but-ai-absence-prompts-early-price-cuts" rel="noreferrer noopener">Apple iPhone 16 Sees 20% Sales Surge in China, But AI Absence Prompts Early Price Cuts</a>
&#8220;Light vehicle production was weak in the third quarter, declining by close to 5% globally. This was driven by a combination of inventory reductions, especially in the Americas and a high comparison base, especially in&nbsp;China,&#8221; said Mikael Bratt, President &amp; CEO.
The CEO indicated that, given recent sales trends and order intake, the company anticipates gaining more market share with domestic Chinese OEMs in the coming years.
Bratt also noted that negotiations for excess inflation compensation with customers have progressed as expected, although a few are still pending.
Outlook: Autoliv now expects full-year 2024 organic sales growth to be 1%, down from the previously anticipated 2%, <a href="https://www.benzinga.com/calendars/guidance">due to unfavorable market mix developments.</a>
With the seasonally strong fourth quarter remaining of the year, the company reaffirmed its guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
Price Action: ALV shares are trading higher by 5.69% to $99.24 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41388050/apples-3nm-push-boosts-taiwan-semis-q3-ai-revenue-set-to-triple-analyst" target="_blank" rel="noreferrer noopener">Apple&#8217;s 3nm Push Boosts Taiwan Semi&#8217;s Q3, AI Revenue Set To Triple: Analyst</a></li>
</ul>

Earnings

Guidance

Movers

General

Autoliv Surges Despite Mixed Q3 Results: Chinese Market Mix Drags  Performance

Piper Sandler analyst Adam Maeder reiterates Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and raises the price target from $495 to $538.

Reiteration

ISRG

Piper Sandler Reiterates Overweight on Intuitive Surgical, Raises Price Target to $538

Canaccord Genuity analyst Kingsley Crane maintains BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) with a Hold and raises the price target from $2.7 to $2.8.

Canaccord Genuity Maintains Hold on BlackBerry, Raises Price Target to $2.8

LYFT

Lyft Option Alert: 1,000 Contracts Of Oct 25 $14 Calls Swept Near The Ask At $0.26; Open Interest 2,062; Stock At $13.75 Ahead Of 11/6 Earnings

Piper Sandler analyst Matt O'Brien reiterates Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $200 to $225.

Piper Sandler Reiterates Overweight on Penumbra, Raises Price Target to $225

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inari Medical (NARI – Research Report) and PROCEPT B...

Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI) and PROCEPT BioRobotics (PRCT)

Kallum Titchmarsh, an analyst from Morgan Stanley, maintained the Buy rating on Inari Medical (NARI – Research Report). The associated price target...

Inari Medical's Resilience and Market Potential Affirm Buy Rating

Mike Kratky, an analyst from Leerink Partners, has initiated a new Hold rating on Inari Medical (NARI). Mike Kratky's rating is based on the dynami...

Inari Medical: Navigating Competitive Threats and Growth Potential in Venous Thromboembolism Treatment

Morgan Stanley analyst Kallum Titchmarsh has maintained their bullish stance on NARI stock, giving a Buy rating on August 28. Kallum Titchmarsh has...

Inari Medical: A Strong Buy on Robust Product Reception and Promising Financial Outlook

In a report released on September 6, Larry Biegelsen from Wells Fargo assigned a Buy rating on Inari Medical (NARI – Research Report), with a price...

Inari Medical: Strong Buy Rating Amidst Anticipated Growth Catalysts and Market Expansion

In a report released today, Adam Maeder from Piper Sandler maintained a Hold rating on Inari Medical (NARI – Research Report), with a price target ...

Piper Sandler Keeps Their Hold Rating on Inari Medical (NARI)

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Inari Medical (NARI – Research Report) yesterday and set a price target of $65.00. L...

Buy Rating for Inari Medical Amid Positive PEERLESS Trial Outlook and Revenue Growth Potential

Bank of America Securities analyst Travis Steed maintained a Buy rating on Inari Medical (NARI – Research Report) today. The company's shares opene...

Bank of America Securities Remains a Buy on Inari Medical (NARI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Day One Biopharmaceuticals (DAWN – Research Report...

Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Inari Medical (NARI)

ClearBridge Small Cap Growth Strategy Q3 2024 Commentary

BCSF

CFCV

CVGW

CYRX

DAWN

FOUR

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

HLNE

INFR

INSM

INTA

IRDM

KVYO

LASR

LRGE

MEDP

MIRM

NARI

PCVX

PGNY

PRCT

SGRY

SMCI

TREX

VRNS

WTFC

WTFCM

WTFCP

YLDE

ZETA

Press Releases

Inari Medical to Announce Second Quarter 2024 Financial Results

Inari Medical Reports Second Quarter 2024 Financial Results

Health Care

Management

Inari Medical Announces Chief Financial Officer Retirement and Succession Plan

Inari Medical to Present at Upcoming Investor Conferences

Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024

Kaskela Law LLC Announces Shareholder Investigation of Inari Medical, Inc. (NASDAQ: NARI) and Encourages Investors to Contact the Firm

Legal

Kaskela Law LLC Announces Shareholder Investigation of Inari Medical, Inc. (NASDAQ: NARI) and Encourages Long-Term NARI Shareholders to Contact the Firm

Comments

Inari Medical

Vendite allo scoperto

Inari Medical (NASDAQ:NARI) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO